GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » The Cooper Companies Inc (NAS:COO) » Definitions » Cash Conversion Cycle

The Cooper (The Cooper) Cash Conversion Cycle

: 212.77 (As of Jan. 2024)
View and export this data going back to 1983. Start your Free Trial

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

The Cooper's Days Sales Outstanding for the three months ended in Jan. 2024 was 61.74.
The Cooper's Days Inventory for the three months ended in Jan. 2024 was 219.84.
The Cooper's Days Payable for the three months ended in Jan. 2024 was 68.81.
Therefore, The Cooper's Cash Conversion Cycle (CCC) for the three months ended in Jan. 2024 was 212.77.


The Cooper Cash Conversion Cycle Historical Data

The historical data trend for The Cooper's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Cooper Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Cash Conversion Cycle
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 193.96 218.36 213.91 184.75 185.41

The Cooper Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cash Conversion Cycle Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 184.49 197.75 194.45 199.13 212.77

Competitive Comparison

For the Medical Instruments & Supplies subindustry, The Cooper's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


The Cooper Cash Conversion Cycle Distribution

For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where The Cooper's Cash Conversion Cycle falls into.



The Cooper Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

The Cooper's Cash Conversion Cycle for the fiscal year that ended in Oct. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=59.3+201.56-75.45
=185.41

The Cooper's Cash Conversion Cycle for the quarter that ended in Jan. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=61.74+219.84-68.81
=212.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


The Cooper  (NAS:COO) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


The Cooper Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of The Cooper's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


The Cooper (The Cooper) Business Description

Traded in Other Exchanges
Address
6101 Bollinger Canyon Road, Suite 500, San Ramon, CA, USA, 94583
The Cooper Companies is one of the largest eye care companies in the U.S. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business and is composed of a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and clariti, Cooper controls roughly a quarter of the U.S. contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the U.S., and controls 17% of the U.S. IUD market.
Executives
Gary S Petersmeyer director 3400 CENTRAL AVENUE, SANTA CLARA CA 95051
Robert S Weiss director, officer: EVP and CFO 6140 STANERIDGE MALL RES #590, PLEASSANTON CA 94503
Agostino Ricupati officer: Sr. VP, Finance & Tax C/O THE COOPER COMPANIES, INC., 6140 STONERIDGE MALL ROAD, SUITE 590, PLEASANTON CA 94588
Warner Gerard H Iii officer: President, CooperVision, Inc. C/O COOPER COMPANIES INC., 6101 BOLLINGER CANYON ROAD, SUITE 500, SAN RAMON CA 94583
Jody S Lindell director 2536 FILLMORE ST., SAN FRANCISCO CA 94115
Cynthia L Lucchese director 7966 N. ILLINOIS STREET, INDIANAPOLIS IN 46260
Nicholas Khadder officer: VP, General Counsel & Corp Sec 2836 JOHNSON AVENUE, ALAMEDA CA 94501
Daniel G Mcbride officer: VP and Senior Counsel 5 EL CORTE, ORINDA CA 94563
Brian G Andrews officer: Treasurer 4300A 17TH STREET, SAN FRANCISCO CA 94114
Maria Rivas director C/O MEDIDATA SOLUTIONS, INC., 350 HUDSON STREET, 9TH FLOOR, NEW YORK NY 10014
White Albert G Iii officer: VP & Treasurer 6790, SPRINGDALE COURT, VICTOR NY 14564
Teresa S Madden director 414 NICOLLET MALL, MINNEAPOLIS MN 55401
Robert D Auerbach officer: President, CSI C/O THE COOPER COMPANIES, INC., SUITE 590, PLEASANTON CA 94588
Holly R Sheffield officer: EVP, CSO C/O THE COOPER COMPANIES, INC., 6140 STONERIDGE MALL ROAD, SUITE 590, PLEASANTON CA 94588
Mark J Drury officer: VP, General Counsel & Sec. C/O COOPERCOMPANIES, 6101 BOLLINGER CANYON ROAD, SUITE 500, SAN RAMON CA 94583

The Cooper (The Cooper) Headlines